{"id":46809,"date":"2012-08-07T18:53:00","date_gmt":"2012-08-07T21:53:00","guid":{"rendered":"http:\/\/revistapesquisa.fapesp.br\/?p=46809"},"modified":"2012-12-07T18:53:59","modified_gmt":"2012-12-07T20:53:59","slug":"investment-in-new-drugs","status":"publish","type":"post","link":"https:\/\/revistapesquisa.fapesp.br\/en\/investment-in-new-drugs\/","title":{"rendered":"Investment in new drugs"},"content":{"rendered":"<p>The Brazilian Development Bank (BNDES) is buying 16% of the capital of Recepta Biopharma, a Brazilian research and development company (R&amp;D) that carries out clinical trials on patients with ovarian tumors, using a drug that is under development, the monoclonal antibody RebmAb100. The bank, through BNDES Participa\u00e7\u00f5es, and two of the company\u2019s private-sector partners, businessmen Em\u00edlio Odebrecht and Jovelino Mineiro, are going to invest R$ 35 million in the company to develop the second phase of the RebmAb100 trials and a second type of monoclonal antibody, RebmAb200. The two drugs may be tested on various types of cancer. \u2028Recepta is directed by Jos\u00e9 Fernando Perez, a retired professor from USP\u2019s Institute of Physics, who was FAPESP\u2019s scientific director between 1993 and 2005. The injection of funds is part of the strategy of the BNDES to strengthen the biotechnology industry by forming partnerships between R&amp;D companies, such as Recepta, and companies responsible for the production and distribution of medication. \u201cWe\u2019ll be taking a significant step toward reducing the vulnerability of the Brazilian National Health System, which is its total dependence on imported supplies of biotechnological products,\u201d Pedro Palmeira from the BNDES told <em>Valor Econ\u00f4mico<\/em>. The monoclonal antibody RebmAb100 has received orphan drug status from the Food and Drug Administration (FDA) of the United States for treating ovarian cancer. This status is granted to drugs that have proved to have effective potential for fighting relatively low incidence diseases, but are of little commercial interest.<\/p>\n","protected":false},"excerpt":{"rendered":"BNDES buys 16% of Brazilian research and development company","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[162],"tags":[232,256],"coauthors":[93],"class_list":["post-46809","post","type-post","status-publish","format-standard","hentry","category-strategies","tag-pharmacology","tag-public-policies"],"acf":[],"_links":{"self":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/46809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/comments?post=46809"}],"version-history":[{"count":0,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/posts\/46809\/revisions"}],"wp:attachment":[{"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/media?parent=46809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/categories?post=46809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/tags?post=46809"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/revistapesquisa.fapesp.br\/en\/wp-json\/wp\/v2\/coauthors?post=46809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}